Last reviewed · How we verify
Eumovate (CLOBETASONE BUTYRATE)
Eumovate (CLOBETASONE BUTYRATE) is a topical glucocorticoid medication that targets the glucocorticoid receptor. It is used to treat atopic dermatitis and eczema. The commercial status of Eumovate is not specified, but it is a small molecule modality. Key safety considerations include potential skin irritation and allergic reactions. As a glucocorticoid, it works by reducing inflammation and immune responses.
At a glance
| Generic name | CLOBETASONE BUTYRATE |
|---|---|
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Atopic dermatitis
- Eczema
Common side effects
Key clinical trials
- Improvement of Psoriasis Patients' Adherence to Topical Drugs (NA)
- Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD) (PHASE3)
- Efficacy of Topical Coal Tar in Children With Atopic Dermatitis (PHASE4)
- Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate 0.05% Cream in Subjects With Eczema for Two Weeks to Evaluate the Efficacy and Safety (PHASE3)
- Evaluation of Anti-inflammatories in the Reduction of Bite Reactions (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eumovate CI brief — competitive landscape report
- Eumovate updates RSS · CI watch RSS